thyroid cancer — TargetMol Chemicals

Cat No.	Product Name	Synonyms	Targets
T15012	Crolibulin	EPC2407	Microtubule Associated
	Crolibulin (EPC2407) is an inhibitor of small molecule tubulin polymerization.		Microtubule Associated
T2988	(-)-Epigallocatechin Gallate	Epigallocatechol Gallate,EGCG	Ferroptosis , Reactive Oxygen Species , HIV Protease , Mitochondrial Metabolism , Endogenous Metabolite , Autophagy
	(-)-Epigallocatechin Gallate (EGCG) is an antioxidant polyphenol flavonoid that inhibits telomerase and DNA methyltransferase. (-)-Epigallocatechin Gallate (EGCG) blocks the activation of EGF receptors and HER-2 receptor...
T1826	PI3K-IN-1	Voxtalisib Analogue,Voxtalisib (SAR245409, XL765) Analogue,XL765,SAR245409	DNA-PK , PI3K
	PI3K-IN-1 (Voxtalisib Analogue) is a dual inhibitor of mTOR/PI3K, mostly for p110γ , also inhibits DNA-PK and mTOR.		DNA-PK , PI3K
T9901A-004	Labetuzumab	IMMU-14,hMN-14,IMMU-100
	Labetuzumab is a humanized anti-carcinoembryonic antigen (CEA) monoclonal antibody with anticancer activity that inhibits tumor growth and is used in the study of thyroid and colorectal cancer (CRC).
T9111	8-Azaadenosine		Adenosine deaminase
	8-Azaadenosine, a powerful ADAR1 (ADAR1) and A-to-I editing inhibitor, effectively blocks RNA editing and suppresses proliferation, 3D growth, invasion, and migration in thyroid cancer cells.		Adenosine deaminase
T77075	Spartalizumab	PDR001	PD-1/PD-L1
	Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that selectively binds to PD-1 at low concentrations and shows high activity. Spartalizumab blocks the interaction with PD-L1 and PD-L2, and can ...		PD-1/PD-L1
T36493	CMLD-2		Apoptosis , HuR
	CMLD-2 is an inhibitor of HuR-ARE interaction (Ki: 350 nM) that competitively binds HuR protein and disrupts its interaction with adenine element-rich (ARE) mRNA targets.CMLD-2 induces apoptosis and exhibits antitumor ef...		Apoptosis , HuR
T39836	Monoethyl phthalate
	Monoethyl phthalate is a metabolite of diethyl phthalate, serving as a urinary biomarker for phthalate exposure, and indicating potential risks of thyroid cancer and benign nodules.
T70759	CUDC-907 mesylate
	CUDC-907 mesylate is a small molecule inhibitor of histone deacetylase and PI3 kinase developed by Curis. It is investigated in clinical trials for the treatment of relapsed or refractory lymphomas, thyroid cancer, multi...
T1656L	Vandetanib Fumarate	HSDB 8198,Zactima,Caprelsa,ZD 6474,Vandetanib
	Vandetanib Fumarate is an orally available tyrosine kinase inhibitor. Vandetanib Fumarate works by blocking RET (REarranged during Transfection), vascular endothelial growth factor receptor (VEGFR-2, VEGFR-3), and epider...
T60935	H-Tyr-Phe-OH
	H-Tyr-Phe-OH (L-Tyrosyl-L-phenylalanine) can be used as the biomarker to distinguish benign thyroid nodules (BTN) from thyroid cancer (TC). H-Tyr-Phe-OH is an orally active Angiotensin-converting enzyme inhibitor with t...
T22552	AD57 (hydrochloride)		Others
	AD57, as polypharmacological cancer therapeutic, is designed to regulate multiple targets related to cancer blocks the receptor tyrosine kinase RET in Drosophila (IC50: 2 nM). AD57 effectively suppresses tyrosine kinase ...		Others
T74893	EGCG-4″-sulfate
	EGCG-4″-sulfate, a predominant polyphenol in green tea, demonstrates notable anticancer, antioxidant, and anti-inflammatory effects, particularly against colorectal cancer, myeloid leukemia, and thyroid carcinoma [1] [2]...
T71267	GNF-8625
	GNE-8525 is a potent and selective pan-TRK inhibitor. GNE-8525 demonstrated potent antiproliferation activity with IC50 = 0.003 μM. In a tumor xenograft model derived from the KM12 cell line, GNE-8525 demonstrated in ...
T63183	RET-IN-9
	RET-IN-9 is a potent inhibitor of RET. RET kinase is a single-channel transmembrane receptor tyrosine kinase that plays an important role in the development of the kidney and enteric nervous system, as well as in the mai...